HOUSTON - Nutex Health Inc. (NASDAQ: NUTX), a diversified healthcare management and operations company, reported a significant increase in its Medicare Advantage (MA) membership during the 2023 annual enrollment period. The company, known for its network of micro hospitals and physician groups, saw its MA membership more than double with the addition of over 2400 new patients across several states.
The enrollment growth was particularly notable in Texas, where Houston Physicians IPA (HPIPA) added over 1900 MA patients. In Florida, Managed Care Insurance Consultants (MCIC) saw an increase of over 200 new MA patients, while Associated Hispanic Physicians IPA (AHP) in California enrolled 300 new members. This surge brings Nutex Health's total MA membership to over 4500.
Chairman and CEO Tom Vo, M.D., MBA, attributed this growth to the company's targeted investments in its population health management division, which have yielded a successful enrollment period. President Warren Hosseinion, M.D., highlighted the company's strategic presence in the top three states for seniors—California, Florida, and Texas—which comprise a quarter of the nation's senior population.
Nutex Health plans to expand its operations further, with intentions to operationalize an IPA in Phoenix, Arizona in 2024 and to enter one or two additional new markets within the year.
The company's Hospital Division operates 20 facilities across eight states, while its Population Health Management Division manages provider networks and offers a cloud-based technology platform that integrates clinical and claims data to support quality care delivery.
This announcement is based on a press release statement, which also includes forward-looking statements subject to risks and uncertainties, such as the company's ability to execute its growth strategy and respond to the demand for its services. These statements are not guarantees of future performance and are subject to various factors that could impact the company's financial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.